Menopause-associated risk of cardiovascular disease
Cardiovascular disease (CVD) is of major concern in women entering menopause. The changing hormonal milieu predisposes them to increased CVD risk, due to a constellation of risk factors, such as visceral obesity, atherogenic dyslipidemia, dysregulation in glucose homeostasis, non-alcoholic fatty liv...
Saved in:
| Published in | Endocrine Connections Vol. 11; no. 4; pp. 1 - 9 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Bioscientifica Ltd
01.04.2022
Bioscientifica |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Cardiovascular disease (CVD) is of major concern in women entering menopause. The changing hormonal milieu predisposes them to increased CVD risk, due to a constellation of risk factors, such as visceral obesity, atherogenic dyslipidemia, dysregulation in glucose homeostasis, non-alcoholic fatty liver disease and arterial hypertension. However, an independent association of menopause per se with increased risk of CVD events has only been proven for early menopause (<45 years). Menopausal hormone therapy (MHT) ameliorates most of the CVD risk factors mentioned above. Transdermal estrogens are the preferable regimen, since they do not increase triglyceride concentrations and they are not associated with increased risk of venous thromboembolic events (VTE). Although administration of MHT should be considered on an individual basis, MHT may reduce CVD morbidity and mortality, if commenced during the early postmenopausal period (<60 years or within ten years since the last menstrual period). In women with premature ovarian insufficiency (POI), MHT should be administered at least until the average age of menopause (50–52 years). MHT is contraindicated in women with a history of VTE and is not currently recommended for the sole purpose of CVD prevention. The risk of breast cancer associated with MHT is generally low and is mainly conferred by the progestogen. Micronized progesterone and dydrogesterone are associated with lower risk compared to other progestogens. |
|---|---|
| AbstractList | Cardiovascular disease (CVD) is of major concern in women entering menopause. The changing hormonal milieu predisposes them to increased CVD risk, due to a constellation of risk factors, such as visceral obesity, atherogenic dyslipidemia, dysregulation in glucose homeostasis, non-alcoholic fatty liver disease and arterial hypertension. However, an independent association of menopause per se with increased risk of CVD events has only been proven for early menopause (<45 years). Menopausal hormone therapy (MHT) ameliorates most of the CVD risk factors mentioned above. Transdermal estrogens are the preferable regimen, since they do not increase triglyceride concentrations and they are not associated with increased risk of venous thromboembolic events (VTE). Although administration of MHT should be considered on an individual basis, MHT may reduce CVD morbidity and mortality, if commenced during the early postmenopausal period (<60 years or within ten years since the last menstrual period). In women with premature ovarian insufficiency (POI), MHT should be administered at least until the average age of menopause (50–52 years). MHT is contraindicated in women with a history of VTE and is not currently recommended for the sole purpose of CVD prevention. The risk of breast cancer associated with MHT is generally low and is mainly conferred by the progestogen. Micronized progesterone and dydrogesterone are associated with lower risk compared to other progestogens. Cardiovascular disease (CVD) is of major concern in women entering menopause. The changing hormonal milieu predisposes them to increased CVD risk, due to a constellation of risk factors, such as visceral obesity, atherogenic dyslipidemia, dysregulation in glucose homeostasis, non-alcoholic fatty liver disease and arterial hypertension. However, an independent association of menopause per se with increased risk of CVD events has only been proven for early menopause (<45 years). Menopausal hormone therapy (MHT) ameliorates most of the CVD risk factors mentioned above. Transdermal estrogens are the preferable regimen, since they do not increase triglyceride concentrations and they are not associated with increased risk of venous thromboembolic events (VTE). Although administration of MHT should be considered on an individual basis, MHT may reduce CVD morbidity and mortality, if commenced during the early postmenopausal period (<60 years or within ten years since the last menstrual period). In women with premature ovarian insufficiency (POI), MHT should be administered at least until the average age of menopause (50–52 years). MHT is contraindicated in women with a history of VTE and is not currently recommended for the sole purpose of CVD prevention. The risk of breast cancer associated with MHT is generally low and is mainly conferred by the progestogen. Micronized progesterone and dydrogesterone are associated with lower risk compared to other progestogens. Cardiovascular disease (CVD) is of major concern in women entering menopause. The changing hormonal milieu predisposes them to increased CVD risk, due to a constellation of risk factors, such as visceral obesity, atherogenic dyslipidemia, dysregulation in glucose homeostasis, non-alcoholic fatty liver disease and arterial hypertension. However, an independent association of menopause per se with increased risk of CVD events has only been proven for early menopause (<45 years). Menopausal hormone therapy (MHT) ameliorates most of the CVD risk factors mentioned above. Transdermal estrogens are the preferable regimen, since they do not increase triglyceride concentrations and they are not associated with increased risk of venous thromboembolic events (VTE). Although administration of MHT should be considered on an individual basis, MHT may reduce CVD morbidity and mortality, if commenced during the early postmenopausal period (<60 years or within ten years since the last menstrual period). In women with premature ovarian insufficiency (POI), MHT should be administered at least until the average age of menopause (50-52 years). MHT is contraindicated in women with a history of VTE and is not currently recommended for the sole purpose of CVD prevention. The risk of breast cancer associated with MHT is generally low and is mainly conferred by the progestogen. Micronized progesterone and dydrogesterone are associated with lower risk compared to other progestogens.Cardiovascular disease (CVD) is of major concern in women entering menopause. The changing hormonal milieu predisposes them to increased CVD risk, due to a constellation of risk factors, such as visceral obesity, atherogenic dyslipidemia, dysregulation in glucose homeostasis, non-alcoholic fatty liver disease and arterial hypertension. However, an independent association of menopause per se with increased risk of CVD events has only been proven for early menopause (<45 years). Menopausal hormone therapy (MHT) ameliorates most of the CVD risk factors mentioned above. Transdermal estrogens are the preferable regimen, since they do not increase triglyceride concentrations and they are not associated with increased risk of venous thromboembolic events (VTE). Although administration of MHT should be considered on an individual basis, MHT may reduce CVD morbidity and mortality, if commenced during the early postmenopausal period (<60 years or within ten years since the last menstrual period). In women with premature ovarian insufficiency (POI), MHT should be administered at least until the average age of menopause (50-52 years). MHT is contraindicated in women with a history of VTE and is not currently recommended for the sole purpose of CVD prevention. The risk of breast cancer associated with MHT is generally low and is mainly conferred by the progestogen. Micronized progesterone and dydrogesterone are associated with lower risk compared to other progestogens. |
| Author | Stevenson, John C Goulis, Dimitrios G Lambrinoudaki, Irene Anagnostis, Panagiotis |
| AuthorAffiliation | 2nd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Medical School, Athens, Greece National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust, London, UK Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece |
| AuthorAffiliation_xml | – name: 2nd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Medical School, Athens, Greece – name: Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece – name: National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust, London, UK |
| Author_xml | – sequence: 1 givenname: Panagiotis orcidid: 0000-0002-8949-4312 surname: Anagnostis fullname: Anagnostis, Panagiotis email: anagnostis@auth.gr organization: Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece – sequence: 2 givenname: Irene surname: Lambrinoudaki fullname: Lambrinoudaki, Irene organization: 2nd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Medical School, Athens, Greece – sequence: 3 givenname: John C surname: Stevenson fullname: Stevenson, John C organization: National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust, London, UK – sequence: 4 givenname: Dimitrios G surname: Goulis fullname: Goulis, Dimitrios G organization: Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35258483$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU9vFCEYh4mpsbX24gcwezQmo_wf5mJiNmttUuNFz-QFXip1dlhhponfXrZbm9ZDOQCBh-cHvC_J0ZQnJOQ1o--ZEvTDZt1x1lEl-mfkhFM5dEIzefRgfkzOar2mrRmmjaAvyLFQXBlpxAkRX3HKO1gqdlBr9glmDKuS6q9VjisPJaR8A9UvI5RVSBWh4ivyPMJY8exuPCU_Pm--r790l9_OL9afLjsnjZo70LTvJWM8DgEjCmQqAvbSccpQchVZ79hg0MhGCsqlMFEz4ZUaZIyKilNycfCGDNd2V9IWyh-bIdnbhVyuLJQ5-RGtDqKnVDsupJFSRueUD6wfwKvgWt9cHw-u3eK2GDxOc4HxkfTxzpR-2qt8YweqtRp0E7y9E5T8e8E6222qHscRJsxLtVyLXojeGNnQNw-z7kP-_XoD3h0AX3KtBeM9wqjdV9Vu1pYzu69qg-l_sE8zzCnv75nGJ4-4lKtP7UUpJg9PpfwFDb2yXw |
| CitedBy_id | crossref_primary_10_1080_13697137_2023_2202809 crossref_primary_10_17826_cumj_1612379 crossref_primary_10_3389_fpsyt_2023_1185782 crossref_primary_10_7759_cureus_65604 crossref_primary_10_1007_s12020_024_03878_1 crossref_primary_10_1111_cen_15136 crossref_primary_10_1016_j_maturitas_2024_107914 crossref_primary_10_1007_s12265_022_10315_z crossref_primary_10_2174_0115701611263345230919122907 crossref_primary_10_1038_s41569_023_00926_7 crossref_primary_10_1177_21501319241307460 crossref_primary_10_1007_s00404_024_07752_3 crossref_primary_10_1016_j_maturitas_2023_107898 crossref_primary_10_1007_s11010_024_05002_3 crossref_primary_10_3389_fendo_2024_1389330 crossref_primary_10_1080_13697137_2024_2441248 crossref_primary_10_1093_ejendo_lvae161 crossref_primary_10_1016_j_maturitas_2022_09_012 crossref_primary_10_1016_j_jacl_2024_04_125 crossref_primary_10_1111_apha_14117 crossref_primary_10_1016_j_phrs_2023_106814 crossref_primary_10_5005_jp_journals_10006_2501 crossref_primary_10_14814_phy2_70076 crossref_primary_10_1007_s12020_023_03421_8 crossref_primary_10_1016_j_ejphar_2024_177031 crossref_primary_10_61411_rsc202590418 crossref_primary_10_18370_2309_4117_2022_65_80_88 crossref_primary_10_3390_life14070849 crossref_primary_10_47360_1995_4484_2023_70_76 crossref_primary_10_1016_j_ebr_2025_100746 crossref_primary_10_3390_jcm12227058 crossref_primary_10_3390_metabo12060539 crossref_primary_10_38124_ijisrt_IJISRT24MAR416 crossref_primary_10_3390_antiox13080973 crossref_primary_10_1097_MJT_0000000000001753 crossref_primary_10_1136_bmj_2022_072612 crossref_primary_10_1055_s_0044_1792122 crossref_primary_10_1186_s12905_024_03452_x crossref_primary_10_1530_EJE_22_0263 crossref_primary_10_3390_biomedicines10123067 crossref_primary_10_1016_j_lfs_2025_123573 crossref_primary_10_1186_s12978_024_01770_9 crossref_primary_10_2174_0115701611280905231227045826 crossref_primary_10_3390_jcm13010195 |
| Cites_doi | 10.1093/eurheartj/ehz455 10.1016/j.maturitas.2010.10.005 10.1111/ijcp.12903 10.1093/eurheartj/ehn408 10.7326/M14-0353 10.1016/j.maturitas.2020.03.006 10.1210/jc.2015-2236 10.1177/1754045313489645 10.1080/13697137.2017.1421925 10.3109/13697137.2015.1094784 10.7326/0003-4819-85-4-447 10.1016/j.maturitas.2015.02.262 10.1038/s41598-021-94189-2 10.1177/2047487314556004 10.2174/1570161116666180709095348 10.1097/MNH.0000000000000404 10.1210/jc.2011-3362 10.1016/j.cmet.2011.08.009 10.1093/eurheartj/ehaa1044 10.1001/jama.288.3.321 10.1001/jama.280.7.605 10.1111/j.1463-1326.2005.00545.x 10.2337/db18-0638 10.1001/jamacardio.2016.2415 10.1097/HJH.0000000000001266 10.1093/eurheartj/ehab484 10.1111/cen.13085 10.1016/0091-7435(91)90006-P 10.1080/13697137.2021.1910232 10.1016/j.maturitas.2021.06.012 10.1016/j.maturitas.2020.03.007 10.7326/0003-4819-89-2-157 10.1016/j.jacc.2016.11.042 10.1016/j.maturitas.2017.02.009 10.1111/j.1365-2362.1993.tb00792.x 10.1001/jama.291.14.1701 10.1001/jama.2019.19191 10.1210/er.2016-1146 10.1016/S0002-9378(98)70634-9 10.1210/jc.2001-012034 10.1056/NEJMoa1505241 10.1530/EJE-18-0602 10.1001/jama.2013.278040 10.1161/01.HYP.0000124670.03674.15 10.1056/NEJM198704303161801 10.1016/S0895-4356(00)00284-5 10.7326/0003-4819-117-12-1016 10.2174/1570161116666180711121949 10.1016/j.maturitas.2018.08.009 10.1210/jc.2015-1864 10.1097/GME.0000000000000352 10.2174/1570161117999190228123237 |
| ContentType | Journal Article |
| Copyright | The authors The authors 2022 The authors |
| Copyright_xml | – notice: The authors – notice: The authors 2022 The authors |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1530/EC-21-0537 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | CrossRef PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| DocumentTitleAlternate | Menopause and cardiovascular disease P Anagnostis et al |
| EISSN | 2049-3614 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_6d37006b2348444fbb5cd179ac5db9ac PMC9066596 35258483 10_1530_EC_21_0537 |
| Genre | Journal Article Review |
| GroupedDBID | 53G 5VS AAFZV ABLYK ABSGY ABSQV ADACO ADBBV AIPOO ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV DIK EBS EE- FRJ GROUPED_DOAJ GX1 H13 INIJC KQ8 M48 M~E OK1 RHF RPM TBS AAKMT AAYXX BTFSW CITATION F9R PGMZT NPM 7X8 5PM |
| ID | FETCH-LOGICAL-b485t-a60774112f9defe3e15fae74b201e425f17b198e84a60302438f613c5594ff503 |
| IEDL.DBID | M48 |
| ISSN | 2049-3614 |
| IngestDate | Wed Aug 27 01:31:57 EDT 2025 Thu Aug 21 13:47:54 EDT 2025 Fri Jul 11 08:53:35 EDT 2025 Thu Jan 02 22:54:11 EST 2025 Thu Apr 24 22:52:39 EDT 2025 Tue Jul 01 02:04:31 EDT 2025 Mon May 09 02:38:20 EDT 2022 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | cardiovascular disease premature ovarian insufficiency early menopause menopausal hormone therapy |
| Language | English |
| License | This work is licensed under a Creative Commons Attribution 4.0 International License. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b485t-a60774112f9defe3e15fae74b201e425f17b198e84a60302438f613c5594ff503 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-8949-4312 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1530/EC-21-0537 |
| PMID | 35258483 |
| PQID | 2637337884 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6d37006b2348444fbb5cd179ac5db9ac pubmedcentral_primary_oai_pubmedcentral_nih_gov_9066596 proquest_miscellaneous_2637337884 pubmed_primary_35258483 crossref_primary_10_1530_EC_21_0537 crossref_citationtrail_10_1530_EC_21_0537 bioscientifica_primary_10_1530_EC_21_0537 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-01 |
| PublicationDateYYYYMMDD | 2022-04-01 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Bristol |
| PublicationTitle | Endocrine Connections |
| PublicationTitleAlternate | Endocr Connect |
| PublicationYear | 2022 |
| Publisher | Bioscientifica Ltd Bioscientifica |
| Publisher_xml | – name: Bioscientifica Ltd – name: Bioscientifica |
| References | Anagnostis (bib6) 2019; 17 Stute (bib55) 2018; 21 Colditz (bib31) 1987; 316 Venetsanaki (bib27) 2019; 17 (bib58) 2021; 42 Xu (bib12) 2011; 14 (bib37) 2013; 121 Walton (bib13) 1993; 23 Robeva (bib26) 2021; 151 Price (bib10) 1998; 178 Lokkegaard (bib45) 2008; 29 Tao (bib33) 2016; 19 Anderson (bib44) 2004; 291 Sherwood (bib19) 2017; 35 Wang (bib28) 2015; 22 Schierbeck (bib48) 2012; 345 Stevenson (bib3) 2021; 24 Reckelhoff (bib18) 2018; 27 Manson (bib43) 2013; 310 Stuenkel (bib38) 2015; 100 Muka (bib32) 2016; 1 Mach (bib57) 2020; 41 Panay (bib51) 2013; 19 Anagnostis (bib39) 2020; 135 Mauvais-Jarvis (bib7) 2017; 38 Toth (bib8) 2000; 904 Schenck-Gustafsson (bib52) 2011; 68 Anagnostis (bib36) 2017; 99 Salpeter (bib21) 2006; 8 Grady (bib40) 1992; 117 Hulley (bib50) 1998; 280 Ferrara (bib11) 2002; 87 Asi (bib54) 2016; 5 bib1 Rossouw (bib42) 2002; 288 Harman (bib49) 2014; 161 Abildgaard (bib9) 2021; 11 (bib59) 2021; 42 Honigberg (bib35) 2019; 322 Roeters van Lennep (bib34) 2016; 23 Kannel (bib29) 1976; 85 Anagnostis (bib22) 2015; 81 Stampfer (bib41) 1991; 20 Slopien (bib56) 2018; 117 Boardman (bib46) 2015; 10 Anagnostis (bib16) 2019; 180 Hodis (bib47) 2016; 374 Anagnostis (bib20) 2020; 135 Anagnostis (bib25) 2016; 70 Tsimikas (bib24) 2017; 69 Reckelhoff (bib17) 2004; 43 Maas (bib2) 2021; 42 Anagnostis (bib23) 2016; 85 Wu (bib15) 2001; 54 Grundy (bib61) 2019; 139 Anagnostis (bib5) 2019; 17 Gordon (bib30) 1978; 89 Yan (bib14) 2019; 68 Mikkola (bib53) 2015; 100 Visseren (bib60) 2021; 42 Harlow (bib4) 2012; 97 |
| References_xml | – volume: 41 start-page: 111 year: 2020 ident: bib57 article-title: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk doi: 10.1093/eurheartj/ehz455 – volume: 5 year: 2016 ident: bib54 article-title: Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis – volume: 68 start-page: 94 year: 2011 ident: bib52 article-title: EMAS position statement: managing the menopause in the context of coronary heart disease doi: 10.1016/j.maturitas.2010.10.005 – volume: 139 start-page: e1082 year: 2019 ident: bib61 article-title: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines – volume: 70 start-page: 967 year: 2016 ident: bib25 article-title: Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options doi: 10.1111/ijcp.12903 – volume: 29 start-page: 2660 year: 2008 ident: bib45 article-title: Hormone therapy and risk of myocardial infarction: a national register study doi: 10.1093/eurheartj/ehn408 – volume: 161 start-page: 249 year: 2014 ident: bib49 article-title: Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial doi: 10.7326/M14-0353 – volume: 135 start-page: 74 year: 2020 ident: bib20 article-title: Early menopause is associated with increased risk of arterial hypertension: a systematic review and meta-analysis doi: 10.1016/j.maturitas.2020.03.006 – volume: 100 start-page: 3975 year: 2015 ident: bib38 article-title: Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline doi: 10.1210/jc.2015-2236 – volume: 19 start-page: 59 year: 2013 ident: bib51 article-title: The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy doi: 10.1177/1754045313489645 – volume: 42 start-page: 2455 year: 2021 ident: bib59 article-title: SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions – volume: 21 start-page: 111 year: 2018 ident: bib55 article-title: The impact of micronized progesterone on breast cancer risk: a systematic review doi: 10.1080/13697137.2017.1421925 – volume: 19 start-page: 27 year: 2016 ident: bib33 article-title: Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis doi: 10.3109/13697137.2015.1094784 – volume: 345 year: 2012 ident: bib48 article-title: Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial – volume: 85 start-page: 447 year: 1976 ident: bib29 article-title: Menopause and risk of cardiovascular disease: the Framingham study doi: 10.7326/0003-4819-85-4-447 – volume: 10 year: 2015 ident: bib46 article-title: Hormone therapy for preventing cardiovascular disease in post-menopausal women – volume: 81 start-page: 62 year: 2015 ident: bib22 article-title: Effects of menopause, gender and age on lipids and high-density lipoprotein cholesterol subfractions doi: 10.1016/j.maturitas.2015.02.262 – volume: 42 start-page: 2439 year: 2021 ident: bib58 article-title: SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe – volume: 11 start-page: 14750 year: 2021 ident: bib9 article-title: Changes in abdominal subcutaneous adipose tissue phenotype following menopause is associated with increased visceral fat mass doi: 10.1038/s41598-021-94189-2 – volume: 23 start-page: 178 year: 2016 ident: bib34 article-title: Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis doi: 10.1177/2047487314556004 – volume: 17 start-page: 564 year: 2019 ident: bib6 article-title: Menopausal hormone therapy and cardiovascular risk: where are we now? doi: 10.2174/1570161116666180709095348 – volume: 27 start-page: 176 year: 2018 ident: bib18 article-title: Gender differences in hypertension doi: 10.1097/MNH.0000000000000404 – volume: 97 start-page: 1159 year: 2012 ident: bib4 article-title: Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging doi: 10.1210/jc.2011-3362 – volume: 14 start-page: 453 year: 2011 ident: bib12 article-title: Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction doi: 10.1016/j.cmet.2011.08.009 – volume: 42 start-page: 967 year: 2021 ident: bib2 article-title: Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European Cardiologists, Gynaecologists, and Endocrinologists doi: 10.1093/eurheartj/ehaa1044 – volume: 288 start-page: 321 year: 2002 ident: bib42 article-title: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial doi: 10.1001/jama.288.3.321 – volume: 280 start-page: 605 year: 1998 ident: bib50 article-title: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group doi: 10.1001/jama.280.7.605 – volume: 8 start-page: 538 year: 2006 ident: bib21 article-title: Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women doi: 10.1111/j.1463-1326.2005.00545.x – volume: 68 start-page: 291 year: 2019 ident: bib14 article-title: Estrogen improves insulin sensitivity and suppresses gluconeogenesis via the transcription factor FoxO1 doi: 10.2337/db18-0638 – volume: 1 start-page: 767 year: 2016 ident: bib32 article-title: Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis doi: 10.1001/jamacardio.2016.2415 – volume: 35 start-page: 975 year: 2017 ident: bib19 article-title: Race and sex differences in cardiovascular alpha-adrenergic and beta-adrenergic receptor responsiveness in men and women with high blood pressure doi: 10.1097/HJH.0000000000001266 – volume: 42 start-page: 3227 year: 2021 ident: bib60 article-title: 2021 ESC guidelines on cardiovascular disease prevention in clinical practice doi: 10.1093/eurheartj/ehab484 – volume: 85 start-page: 733 year: 2016 ident: bib23 article-title: Effects of gender, age and menopausal status on serum apolipoprotein concentrations doi: 10.1111/cen.13085 – volume: 20 start-page: 47 year: 1991 ident: bib41 article-title: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence doi: 10.1016/0091-7435(91)90006-P – volume: 24 start-page: 474 year: 2021 ident: bib3 article-title: Cardiometabolic health in premature ovarian insufficiency doi: 10.1080/13697137.2021.1910232 – volume: 151 start-page: 22 year: 2021 ident: bib26 article-title: The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause doi: 10.1016/j.maturitas.2021.06.012 – volume: 904 start-page: 502 year: 2000 ident: bib8 article-title: Menopause-related changes in body fat distribution – volume: 135 start-page: 82 year: 2020 ident: bib39 article-title: Menopause symptom management in women with dyslipidemias: an EMAS clinical guide doi: 10.1016/j.maturitas.2020.03.007 – volume: 89 start-page: 157 year: 1978 ident: bib30 article-title: Menopause and coronary heart disease. The Framingham Study doi: 10.7326/0003-4819-89-2-157 – volume: 69 start-page: 692 year: 2017 ident: bib24 article-title: A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies doi: 10.1016/j.jacc.2016.11.042 – volume: 99 start-page: 27 year: 2017 ident: bib36 article-title: The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: a systematic review and meta-analysis doi: 10.1016/j.maturitas.2017.02.009 – volume: 23 start-page: 466 year: 1993 ident: bib13 article-title: The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women doi: 10.1111/j.1365-2362.1993.tb00792.x – volume: 291 start-page: 1701 year: 2004 ident: bib44 article-title: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial doi: 10.1001/jama.291.14.1701 – volume: 322 start-page: 2411 year: 2019 ident: bib35 article-title: Association of premature natural and surgical menopause with incident cardiovascular disease doi: 10.1001/jama.2019.19191 – volume: 38 start-page: 173 year: 2017 ident: bib7 article-title: Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications doi: 10.1210/er.2016-1146 – volume: 178 start-page: 101 year: 1998 ident: bib10 article-title: Estrogen regulation of adipose tissue lipoprotein lipase – possible mechanism of body fat distribution doi: 10.1016/S0002-9378(98)70634-9 – volume: 87 start-page: 4166 year: 2002 ident: bib11 article-title: Differences in adipose tissue metabolism between postmenopausal and perimenopausal women doi: 10.1210/jc.2001-012034 – volume: 374 start-page: 1221 year: 2016 ident: bib47 article-title: Vascular effects of early versus late postmenopausal treatment with estradiol doi: 10.1056/NEJMoa1505241 – volume: 180 start-page: 41 year: 2019 ident: bib16 article-title: Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis doi: 10.1530/EJE-18-0602 – volume: 310 start-page: 1353 year: 2013 ident: bib43 article-title: Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials doi: 10.1001/jama.2013.278040 – volume: 43 start-page: 918 year: 2004 ident: bib17 article-title: Novel mechanisms responsible for postmenopausal hypertension doi: 10.1161/01.HYP.0000124670.03674.15 – volume: 316 start-page: 1105 year: 1987 ident: bib31 article-title: Menopause and the risk of coronary heart disease in women doi: 10.1056/NEJM198704303161801 – volume: 54 start-page: 117 year: 2001 ident: bib15 article-title: The impact of years since menopause on the development of impaired glucose tolerance doi: 10.1016/S0895-4356(00)00284-5 – volume: 117 start-page: 1016 year: 1992 ident: bib40 article-title: Hormone therapy to prevent disease and prolong life in postmenopausal women doi: 10.7326/0003-4819-117-12-1016 – ident: bib1 – volume: 17 start-page: 546 year: 2019 ident: bib27 article-title: Menopause and non-alcoholic fatty liver disease: a review focusing on therapeutic perspectives doi: 10.2174/1570161116666180711121949 – volume: 117 start-page: 6 year: 2018 ident: bib56 article-title: Menopause and diabetes: EMAS clinical guide doi: 10.1016/j.maturitas.2018.08.009 – volume: 100 start-page: 4588 year: 2015 ident: bib53 article-title: Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy doi: 10.1210/jc.2015-1864 – volume: 121 start-page: 887 year: 2013 ident: bib37 article-title: ACOG committee opinion no. 556: postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism – volume: 22 start-page: 667 year: 2015 ident: bib28 article-title: Prevalence of nonalcoholic fatty liver disease and its metabolic risk factors in women of different ages and body mass index doi: 10.1097/GME.0000000000000352 – volume: 17 start-page: 543 year: 2019 ident: bib5 article-title: Menopause and its cardiometabolic consequences: current perspectives doi: 10.2174/1570161117999190228123237 |
| SSID | ssj0000816830 |
| Score | 2.439017 |
| SecondaryResourceType | review_article |
| Snippet | Cardiovascular disease (CVD) is of major concern in women entering menopause. The changing hormonal milieu predisposes them to increased CVD risk, due to a... |
| SourceID | doaj pubmedcentral proquest pubmed crossref bioscientifica |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1 |
| SubjectTerms | cardiovascular disease early menopause menopausal hormone therapy premature ovarian insufficiency Review |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT8MwDI7QThxAvCkvFYGQOFRrm6RNjzANISQ4gcQtalJHTIIOse3Av8dOy7SiCS5ccmjdNrKd2K6dz4ydG1OVcZaKSDgauFGR4XkVVWkeKyfQQTV0wPn-Ibt9EnfP8nmh1RfVhDXwwA3j-lnFc9QMk3KhhBDOGGkr1KLSysrgSLsv2ryFYMrvwdROgsctHqnkcX84iFIMnCU1PF8zowYp0pfjdE2SR-5f5m7-rJpcMEM3G2y99R_Dq2bem2wF6i22fVVj7Pz2GV6EvqLT_yrfZvweaoyJZxOIylYKUIVUTB6OXWg7lahhm6nZYU83w8fBbdQ2SYiMUHIalVmMHhx6Ta6owAGHRLoScmHQsgMuSJfkJikUKIGUnPAHlUMTbjGSEM7JmO-yXj2uYZ-FlBQEadFjMVa4wpoMH0pLUIBOieUQsMsu4_R7g4ihKZJAJuvhQKeJJiYj7TdPtW3RxqnpxetS2rM57W9vvCbRzCkIF9tfQG3Rrbbov7QlYKffgtW4jig5UtYwnk10mvGcE7i-CNheI-j5pwgyVgnFA5Z3VKAzl-6devTisboLSm0V2cF_TP6QraZ0-MLXDR2x3vRjBsfoEk3Nidf-L8I5CYk priority: 102 providerName: Directory of Open Access Journals |
| Title | Menopause-associated risk of cardiovascular disease |
| URI | http://dx.doi.org/10.1530/EC-21-0537 https://www.ncbi.nlm.nih.gov/pubmed/35258483 https://www.proquest.com/docview/2637337884 https://pubmed.ncbi.nlm.nih.gov/PMC9066596 https://doaj.org/article/6d37006b2348444fbb5cd179ac5db9ac |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6VcgGpqFAoy6MKAiFxMCS2EzsHVJXVlgppObHS3qzYsWmlki37kOi_Z8brXRG0Qlx8SMZ5jB_zjT3-BuCNtW2TV1wyGagQVjMrVMtarnIdJAJUSwecx1-ri4n8Mi2ne7DJ35kUuNjp2lE-qcn8-v2vn7enOOA_xuw9Iv8wGjKOPnEp1B24ixZJUSaDcYL5cUam5BIx7QhHQMwEmqTEVNqvfh8O7NWaQzIG6vSNVeT03wVE_46n_MNAnR_Cg4Qss7N1V3gIe757BEdnHXrVP26zt1mM9YyL6Ecgxr5Db3m18KxJ7ePbjMLMs1nIXC9GNUt7OI9hcj76NrxgKX0Cs1KXS9ZUOWI7xFOhbn3wwhdlaLySFm2-x6EaCmWLWnstUVIQM6EOaNwd-hgyhDIXT2C_m3X-KWS0XehLh1jGOhlqZyusxBuvPcIVJ_wA3vUVZ27WXBmGfAxUshkNDS8MKRllNzo1LvGQUzqM652yr7ey_3riJ2qarQQxZscLs_l3kwagqVqhcIaxXEgtpQzWlq7F2ahxZWuxHMCrTcMaHGG0bdJ0frZaGF4JJYh2Xw7geN3Q21cRmayWWgxA9bpA71v6d7qry8jiXdOmV109-69ffA73OJ27iCFDL2B_OV_5l4iGlvYkriJg-XlanMRu_xspvgec |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Menopause-associated+risk+of+cardiovascular+disease&rft.jtitle=Endocrine+Connections&rft.au=Anagnostis%2C+Panagiotis&rft.au=Lambrinoudaki%2C+Irene&rft.au=Stevenson%2C+John+C&rft.au=Goulis%2C+Dimitrios+G&rft.date=2022-04-01&rft.issn=2049-3614&rft.eissn=2049-3614&rft.volume=11&rft.issue=4&rft_id=info:doi/10.1530%2FEC-21-0537&rft.externalDBID=n%2Fa&rft.externalDocID=10_1530_EC_21_0537 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2049-3614&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2049-3614&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2049-3614&client=summon |